Premium
SALMON AND HUMAN CALCITONIN‐LIKE PEPTIDES IN MAN
Author(s) -
TOBLER P. H.,
TSCHOPP F. A.,
DAMBACHER M. A.,
FISCHER J. A.
Publication year - 1984
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1984.tb00081.x
Subject(s) - calcitonin , radioimmunoassay , endocrinology , medicine , calcitonin gene related peptide , gel permeation chromatography , chemistry , salmon calcitonin , peptide , thyroid carcinoma , thyroid , neuropeptide , biochemistry , receptor , organic chemistry , polymer
SUMMARY Calcitonin‐like peptides have been identified in the serum of normal subjects and of medullary thyroid carcinoma (MTC) patients. Using specific homologous radioimmunoassays (RIA) in combination with reversed‐phase high performance liquid chromatography and gel permeation chromatography under denaturing conditions, we have recognized major components which coeluted with human calcitonin‐(1–32), PDN‐21, a carboxyl‐terminal flanking peptide derived from the calcitonin mRNA sequence, and salmon calcitonin‐(1–32). An additional 12000 molecular weight peak possibly represents a human calcitonin‐PDN‐21 polyprotein. In both the human calcitonin‐(1–32) (normal value < 0·043 ngEq/ml; MTC 140·80 ngEq/ml, mean value±SEM) and the PDN‐21 (normal value <0·050 ngEq/ml; MTC 33·6±16·5 ngEq/ml) RIAs, serum levels were increased in MTC patients. Circulating levels of the salmon calcitonin‐like peptide were indistiguishable between normal subjects (0·038 ± 0·006 ngEq/ml) and MTC patients (0·037 ± 0·011 ngEq/ml).